東陽光藥(01558.HK):自研產品甘精胰島素注射液獲批上市
格隆匯10月29日丨東陽光藥(01558.HK)宣佈,公司自主研究及開發的產品甘精胰島素注射液已獲中國國家藥品監督管理局審批完畢並獲准上市。
甘精胰島素屬於人胰島素類似物,具有長效降糖效果,適用於治療需要採用胰島素來維持正常血糖水平的糖尿病患者。根據艾昆緯中國數據顯示,2020年中國糖尿病領域藥物銷售金額約為46.6億美元,較2019年增長7.1%,其中人胰島素及其類似物類藥物銷售金額佔糖尿病領域藥物總市場銷售金額的約46.1%,是糖尿病治療領域最主要的用藥品種。
該產品為集團獲批上市的生物製品藥物,累計投入研發費用約人民幣15,310.18萬元。此外,集團在糖尿病治療領域擁有全面規劃,佈局了完整的產品線。該產品成功獲批上市,有益於拓展集團內分泌及代謝治療領域業務,並進一步豐富了集團的產品組合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.